| Prev Close | 104.80 |
| Open | 104.44 |
| Day Low/High | 102.90 / 105.19 |
| 52 Wk Low/High | 72.13 / 122.15 |
| Volume | 3.57M |
Medtronic Plc (MDT)
104.35
0.45
0.43
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1344.21B |
| Market Cap | 144.64B |
| P/E Ratio | 32.71 |
| Div & Yield | N.A. (N.A) |
Latest News
Real Money Post Industrial Average Outperforms, Despite Outbreak
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
The Fed Has Our Backs, Trading Thoughts, 'Facebook Shops'
As State economies begin the slow process of reopening, the Fed is there to support market function. Facebook's latest e-commerce foray has investors cheering.
Medtronic Stock Is in 'No Man's Land'
The medical device company is scheduled to report earnings this week.
Medtronic Presents an Opportunity, and Not Just Because It Makes Ventilators
The charts of the producer of medical equipment are holding up well, though its shares eventually could run into resistance.
Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
Jim Cramer: Rate Cut No Cure for Coronavirus
But don't throw up your arms yet -- here are names that could be golden opportunities.
Three Strategies for Income Investors
For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.
Does the Macro Matter for Equities? Salesforce Dreamforce Begins, Trading Apple
Tuesday's Dreamforce features a discussion between Salesforce's Marc Benioff and Apple's Tim Cook.
Medtronic Set to Trade Higher Unless Earnings Derail the Rally
Let's see what the charts have to say.
Medtronic Operating Toward Renewed Gains
After correction, the medical device maker could see longer-term gains to the $150-$161 area.
7 Medical Products Stocks With the Right Prescription for Gains
Top picks in the fast-growing medical products market.
Medtronic Hits Our Price Target: Time to Take Profits?
A follow-up to our story in June.
Profit Taking, Rate Cuts and a Play on Zscaler: Market Recon
Evaluating the market and policy discussion ahead of Jackson Hole, and how I am playing Zscaler on this weakness.
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Dexcom Looks Like It Can Finally Break Out on the Topside
Let's check the charts and indicators on the glucose-monitoring company.
Real Money Post-Industrial Index Continues to Outperform Major Market Indices
Amid May's market turbulence, the RMPIA was buoyed by the more than 4% rise from Medtronic.
Medtronic Is Edging Closer to an Upside Breakout on the Charts
No one knows their business as well as the CEO.
Trade War Heats Up, Fundamental Analysis, Boeing on the Hot Seat: Market Recon
China's President Xi has obviously found surrender distasteful.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
A Technical Strategy for Tandem Diabetes Care
Are we late to the game with the stock up so much?
Real Money Post-Industrial Average Shines in January, Outperforming S&P 500
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
Medtronic Stock Is Showing Promise on the Daily Chart
Here's how to trade MDT, going long.
8 Top Year-End Trading Ideas for Bargain Hunters
These eight S&P 500 stocks have some of the worst returns year-to-date and represent a diverse roster of promising bounce candidates.
Medtronic Is Testing the 200-Day Average and I Am Not Too Optimistic
Prices are testing the October and November lows and also testing the rising 200-day moving average line.
Rattled? The Only Obstacle Is the One in Front of You: Market Recon
Everyone gets knocked down. What is different about you is that you are as tough as these markets.
Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half
Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.
